Short-term application of dexamethasone enhances bone morphogenetic protein-7-induced ectopic bone formation in vivo

Journal of Trauma - Injury, Infection and Critical Care

Volumn 69, Issue 6, 2010, Pages 1473-1480

  Spiro, Alexander S ^a   Timo Beil, F ^a   Schinke, Thorsten ^a   Schilling, Arndt F ^a   Eulenburg, Christine ^a   Rueger, Johannes M ^a   Amling, Michael ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

BMP 7; Dexamethasone; Ectopic bone formation; Histomorphometry; Microcomputed tomography ( CT)

Indexed keywords

DEXAMETHASONE; OSTEOGENIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; CONTROLLED STUDY; FEMALE; HAMSTRING; HISTOLOGY; IN VIVO STUDY; LUMBAR VERTEBRA; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; RADIOGRAPHY;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOGENESIS; THIGH; X-RAY MICROTOMOGRAPHY;

EID: 78650828792     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181dc59e4     Document Type: Article

References (25)

1. Lane NE. An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2001;27:235-253.
2. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941-955.
3. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
4. Spreafico A, Frediani B, Capperucci C, et al. Osteogenic growth peptide effects on primary human osteoblast cultures: potential relevance for the treatment of glucocorticoid-induced osteoporosis. J Cell Biochem. 2006; 98:1007-1020.
5. Shalhoub V, Conlon D, Tassinari M, et al. Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes. J Cell Biochem. 1992;50:425-440.
6. Igarashi M, Kamiya N, Hasegawa M, Kasuya T, Takahashi T, TakagiM. Inductive effects of dexamethasone on the gene expression of Cbfa1, Osterix and bone matrix proteins during differentiation of cultured primary rat osteoblasts. J Mol Histol. 2004;35:3-10.
7. Song IH, Caplan AI, Dennis JE. In vitro dexamethasone pretreatment enhances bone formation of human mesenchymal stem cells in vivo. J Orthop Res. 2009;27:916-921.
8. Cabral MC, Costa MA, Fernandes MH. In vitro models of periodontal cells: a comparative study of long-term gingival, periodontal ligament and alveolar bone cell cultures in the presence of beta-glycerophosphate and dexamethasone. J Mater Sci Mater Med. 2007;18:1079-1088.
9. Chaudhary LR, Hofmeister AM, Hruska KA. Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone. 2004;34:402-411.
10. Andrades JA, Santamaría JA, Nimni ME, Becerra J. Selection and amplification of a bone marrow cell population and its induction to the chondro-osteogenic lineage by rhOP-1: an in vitro and in vivo study. Int J Dev Biol. 2001;45:689-693.
11. Jäger M, Fischer J, Dohrn W, et al. Dexamethasone modulates BMP-2 effects on mesenchymal stem cells in vitro. J Orthop Res. 2008;26: 1440-1448.
12. Liu Y, Titus L, Barghouthi M, Viggeswarapu M, Hair G, Boden SD. Glucocorticoid regulation of human BMP-6 transcription. Bone. 2004; 35:673-681.
13. Sampath TK, Maliakal JC, Hauschka PV, et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem. 1992;267:20352-20362.
14. Salkeld SL, Patron LP, Barrack RL, Cook SD. The effect of osteogenic protein-1 on the healing of segmental bone defects treated with autograft or allograft bone. J Bone Joint Surg Am. 2001;83:803-816.
15. Kloen P, Di Paola M, Borens O, et al. BMP signaling components are expressed in human fracture callus. Bone. 2003;33:362-371.
16. Ripamonti U, Van Den Heever B, Sampath TK, Tucker MM, Rueger DC, Reddi AH. Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (hOP-1, bone morphogenetic protein-7). Growth Factors. 1996;13:273-289.
17. Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br. 1999;81:710-718.
18. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83:151-158.
19. White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, McKee MD. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop. 2007;31:735-741.
20. McLaughlin F, Mackintosh J, Hayes BP, et al. Glucocorticoidinduced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone. 2002; 30:924-930.
21. Amling M, Priemel M, Holzmann T, et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology. 1999;140:4982-4987.
22. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res. 1987;6:595-610.
23. Schilling AF, Schinke T, Münch C, et al. Increased bone formation in mice lacking apolipoprotein E. J Bone Miner Res. 2005;20:274-282.
24. Leclerc N, Luppen CA, Ho VV, et al. Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol. 2004;33:175-193.
25. Luppen CA, Smith E, Spevak L, Boskey AL, Frenkel B. Bone morphogenetic protein-2 restores mineralization in glucocorticoidinhibited MC3T3-E1 osteoblast cultures. J Bone Miner Res. 2003; 18:1186-1197.